Could a diabetes drug shield the liver? new trial tests empagliflozin in cirrhosis

NCT ID NCT07322237

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding empagliflozin (a diabetes drug) to standard carvedilol treatment can prevent liver decompensation events and death in 400 adults with cirrhosis and left ventricular diastolic dysfunction (stiff heart). Participants will receive either empagliflozin plus carvedilol or a placebo plus carvedilol for up to 2 years. The goal is to see if the combination reduces complications like bleeding, ascites, or kidney injury.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Empagliflozin and Carvedilol
What this could lead to
If it works, this combination could reduce the risk of serious liver complications and improve survival in people with cirrhosis and heart stiffness.
What could go wrong
This is a single-center Phase 4 trial, so results may not apply broadly. The drug may cause side effects like infections or low blood pressure, and the benefit over carvedilol alone is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOMETABOLIC RISK FACTORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • PGIMER Chandigarh

    RECRUITING

    Chandigarh, 160012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.